Authors
Muhammad Ary Zucha^1,2, Vincentius Simeon Weo Budhyanto³, Widha Apriani Priadi¹, Faizah Dwi Tirtasari⁴, Moh Nailul Fahmi¹, Addin Trirahmanto¹, Ardhanu Kusumanto¹, Heru Pradjatmo¹, Siti Salima ², Ali Budi Harsono ², Gatot Nyarumenteng Adhipurnawan Winarno ², Dodi Suardi², Nadia Yasmine⁵, Agil Wahyu Wicaksono ⁶, Laurens David Paulus⁷, Muhammad Yusuf⁸, Andi Kurniadi ⁴

Affiliations

¹Department of Obstetrics and Gynecology, Division of Oncology Gynecology, Universitas Gadjah Mada – Sardjito Central Hospital, Yogyakarta, Indonesia; ²Department of Obstetrics and Gynecology, Division of Oncology Gynecology Universitas Padjadjaran-Hasan Sadikin Central Hospital, Bandung, West Java, Indonesia; ³Department of Human Genetics, Yayasan Satriabudi Dharma Setia, Tangerang, Banten, Indonesia; ⁴Department of Pathology Anatomy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; ⁵Department of Nutrition, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; ⁶Department of Biomedical Science, Faculty of Medicine, Universitas Institut Pertanian Bogor, Bogor, West Java, Indonesia; ⁷Department of Obstetrics and Gynecology, Prof. WZ. Johanes Hospital, Nusa Tenggara Timur, Indonesia; ⁸Department of Obstetrics and Gynecology, Dharmais Central Hospital, Jakarta, Indonesia

Background

• Inflammation plays a central role in ovarian cancer, and IL-6-secreting tumors may carry altered genetic profiles.

• Studies combining IL-6 measurement with genomic profiling are lacking.

Methods

• 45 women undergoing surgery for ovarian tumors (18 malignant, 19 benign, 8 borderline).

• IL-6 was measured in serum and tumor fluid by ELISA.

• High-IL-6 cancers underwent whole-genome sequencing (ONT).

Key Results

• IL-6 levels were consistent between serum and tumor fluid.

• Malignant tumors secreted significantly more IL-6 than benign ones (p = 0.027).

• IL-6-secreting cancers showed alterations in genes including MTRF1, IL-10, IL-6, APC, PAX8, PTGS2, and PACERR.

Discussion & Conclusion

• Ovarian malignancy is marked by high secretion of pro-inflammatory cytokines.

• Inflammation may disrupt the genetic landscape, offering candidate biomarkers and therapeutic targets for future validation.

Related SDGs

SDG 3: Good Health and Well-Being – Advancing biomarker discovery in ovarian cancer

Journal Information

Journal: International Journal of Women’s Health

DOI: https://doi.org/10.2147/IJWH.S589918